The BOPA Cancer Consultant Pharmacist Credentialing Support Series is back

BOPA are holding a nine month supportive webinar series for pharmacists who are credentialing as consultant pharmacists with the RPS.

Join in this relaxed forum to discuss about your portfolio submission, discuss evidence for outcomes and network with colleagues.

Each month will hold a different theme, this month’s session is the third of the series in 2025 and the topic is Leadership Domain.

Third session: Monday 28th April 1:30pm

Speaker:
Dharmisha Chauhan – Consultant Pharmacist

Pharmacists actively collating evidence and looking to submit in the next 18 months are welcome to join.

Netty Cracknell and Jo Parkes will be chairing and facilitating conversations.

Please note: This series is available to BOPA paid members only. Click here to join or renew your BOPA paid membership.

For more information click here: https://www.bopa.org.uk/pharmacist-cancer-consultant-credentialing-support-series/

Thank you
The BOPA E&T Subcommittee

Latest News

By BOPA Research Committee on 27th April 2025

SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment

Dear BOPA member, Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer,…

Read article
By BOPA on 27th April 2025

Further monographs for use of immunosuppressants in Immune-related adverse events (irAEs)

Earlier this year the BOPA Immunotherapy Group wrote, and published, four monographs to help health care professionals care for patients with immune-related adverse events. As a group we are pleased…

Read article
By BOPA Committee on 27th April 2025

Women for Oncology UK Spring Webinar

The Spring webinar for Women for Oncology UK is on the 16th May, to sign up click the link below. Women For Oncology UK Spring Webinar Tickets, Wed 14 May…

Read article
By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article